Development of a high-throughput opsonophagocytic assay for the determination of functional antibody activity against Streptococcus pyogenes using bioluminescence.

The lack of standardised protocols for the assessment of functional antibodies has hindered Streptococcus pyogenes research and the development of vaccines. A robust, high throughput opsonophagocytic bactericidal assay to determine protective antibodies in human and rabbit serum has been developed that utilises bioluminescence as a rapid read out.

• Publication year

  2017

• Venue

  Journal of Microbiological Methods

• Publication date

  2017-03-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.mimet.2017.01.010PMID 28115206
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Post-Streptococcal Autoimmune Sequelae: Rheumatic Fever and Beyond

  2016cited by this paper
• Status of research and development of vaccines for Streptococcus pyogenes.

  2016cited by this paper
• Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus

  2015cited by this paper
• Acute rheumatic fever and rheumatic heart disease

  2015cited by this paper
• Post-infectious group A streptococcal autoimmune syndromes and the heart.

  2015cited by this paper
• Working towards a group A streptococcal vaccine: report of a collaborative Trans-Tasman workshop.

  2014cited by this paper
• Survey of the bp/tee genes from clinical group A streptococcus isolates in New Zealand - implications for vaccine development.

  2014cited by this paper
• Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study.

  2014cited by this paper
• Structural Conservation, Variability, and Immunogenicity of the T6 Backbone Pilin of Serotype M6 Streptococcus pyogenes

  2014cited by this paper
• Disease Manifestations and Pathogenic Mechanisms of Group A Streptococcus

  2014cited by this paper
• Galleria mellonella larvae as an infection model for group A streptococcus

  2013cited by this paper
• Toxin–antitoxin-stabilized reporter plasmids for biophotonic imaging of Group A streptococcus

  2013cited by this paper
• Group A streptococcal vaccines: facts versus fantasy

  2009cited by this paper
• Pathogenesis of group A streptococcal infections and their sequelae.

  2008cited by this paper
• Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: implications for treatment of streptococcal toxic shock syndrome.

  2006cited by this paper
• Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation.

  2006cited by this paper
• The global burden of group A streptococcal diseases.

  2005cited by this paper
• PERSISTENCE OF TYPE-SPECIFIC ANTIBODIES IN MAN FOLLOWING INFECTION WITH GROUP A STREPTOCOCCI

  1959cited by this paper

• Recent Advances in Pathogenic Streptococcus Vaccine Development.

  2019cites this paper
• WHO/IVI global stakeholder consultation on group A Streptococcus vaccine development: Report from a meeting held on 12-13 December 2016.

  2018cites this paper
• Protein adhesins as vaccine antigens for Group A Streptococcus.

  2018cites this paper
• Mucosal vaccination with pili from Group A Streptococcus expressed on Lactococcus lactis generates protective immune responses

  2017cites this paper